Study to Evaluate the Efficacy and Safety of CDK4/6 Inhibitor SHR6390 Combined With Pyrotinib in the Treatment of HER2-positive Advanced Breast Cancer
Study Details
Study Description
Brief Summary
The main purpose of this study was to observe the efficacy and safety of treatment with pyrotinib and CDK4/6 inhibitor SHR6390 for HER2-positive metastatic breast cancer.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Phase 2 |
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Experimental: Experimental: Pyrotinib + SHR6390 Pyrotinib combine with SHR6390 should be administrate to all subjects. pyrotinib 400mg qd combined with SHR 6390 125mg qd |
Drug: Pyrotinib combine with SHR6390
SHR6390 is a novel small molecule inhibitor specifically targeting the CDK4/6 pathway. Pyrotinib is an irreversible pan-ErbB inhibitor which shows promising antitumour activity in patients with HER2-positive metastatic breast cancer
|
Outcome Measures
Primary Outcome Measures
- Objective Response Rate [from enrollment to progression or death (for any reason), assessed up to 100 months]
CR+PR
Secondary Outcome Measures
- PFS [from enrollment to progression or death (for any reason),assessed up to 100 months]
Progression-Free Survival
- OS [from enrollment to death (for any reason).assessed up to 100 months]
Overall Survival
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Local recurrent or metastatic breast cancer suitable for chemotherapy, confirmed histologically.
-
HER2-positive breast cancer(according to 2018 ASCO/CAP HER2 test guideline).
-
Patients with HER2-positive metastatic breast cancer who had received ≤ 1-line treatment in the past;
-
18-70 years old.
-
ECOG PS 0～1.
-
life expectancy is not less than 12 weeks.
-
at least one measurable lesion according to RECIST 1.1.
-
ANC ≥ 2.0×109/L,PLT ≥ 100×109/L,Hb ≥ 90 g/L;TBIL≤1.5ULN；ALT and AST≤3×ULN（ALT and AST≤5×ULN if liver metastasis）;BUN and Cr≤1.5×ULN
-
LVEF ≥ 50% and QTc≤470 ms.
Exclusion Criteria:
-
Patients with symptomatic brain metastasis;
-
Unable to swallow, chronic diarrhea and intestinal obstruction, there are many factors affecting drug use and absorption.
-
patient who received radiotherapy, chemotherapy, surgery (excluding local puncture) or molecular targeted therapy within 4 weeks before admission; those who received anti-tumor endocrine therapy after screening period
-
Participated in other drug clinical trials within 4 weeks before admission
-
Tyrosine kinase inhibitors targeting HER2 (Neratinib, Lapatinib, pyrotinib, etc.) have been used or are being used in the past.
-
Other malignant tumors, excluding cured cervical carcinoma in situ, skin basal cell carcinoma or skin squamous cell carcinoma, have been diagnosed in the past five years.
-
A history of immunodeficiency, including HIV positive, HCV,, or other acquired, congenital immunodeficiency disorders, or organ transplantation, is known.
-
Has suffered from any heart disease
-
Female patients during pregnancy and lactation, fertile women with positive baseline pregnancy tests or women of childbearing age who are unwilling to take effective contraceptive measures throughout the trial
-
According to the judgement of the researchers, there are concomitant diseases that seriously endanger the safety of patients or affect the completion of research (including, but not limited to, severe hypertension, severe diabetes, active infections, etc.).
-
Moderate infection occurs within 4 weeks before the first administration (e.g. intravenous drip of antibiotics, antifungal or antiviral drugs according to clinical criteria), fever（> 38.5 ℃） of unknown origin occurs during the screening period/before the first administration.
-
Researchers believe that patients are not suitable for any other situation in this study.
Contacts and Locations
Locations
No locations specified.Sponsors and Collaborators
- Sun Yat-sen University
- Jiangsu HengRui Medicine Co., Ltd.
Investigators
None specified.Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- HR-BLTN-014